Plus Therapeutics (STU:XMP0) Total Stockholders Equity : €-8.55 Mil (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Plus Therapeutics Total Stockholders Equity?

Plus Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €-8.55 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Plus Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was €-1.45. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Plus Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 was -0.38.

Plus Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Plus Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics Total Stockholders Equity Chart

Plus Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

2.49

9.59

6.08

-1.24

-8.55

Plus Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															-1.24	-4.45	-7.08	-4.66	-8.55

Plus Therapeutics (STU:XMP0) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Plus Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-8.546	-	0)	/	5.896
	=	-1.45

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Plus Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.186	+	0.03)	/	-8.546
	=	-0.38

Plus Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Plus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (STU:XMP0) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

PSTV:USA

Address

2710 Reed Road, Suite 160, Houston, TX, USA, 77051

Website

https://www.plustherapeutics.com

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Plus Therapeutics Headlines

No Headlines